Biocon Ltd Q4 FY25 Earnings Analysis
Published 20 Aug 2026 | Pharmaceuticals & Biotechnology | Market Cap: ₹69.3K Cr
Price
₹413
Market Cap
₹69.3K Cr
P/E Ratio
95.3
How does Biocon Ltd rank in Pharmaceuticals & Biotechnology?
Compare Biocon Ltd against every Pharmaceuticals & Biotechnology company this quarter on revenue, margins and earnings-call signals.
Biocon Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹4.5K Cr, net profit ₹199 Cr.
Full financials →Earnings Summary
Biosimilars: Expect accelerated growth driven by new biosimilar launches with increasing market shares, e.g., Stelara and insulins expanding across 80+ countries. FY'25 saw a consolidation and transition phase setting up for accelerated growth, with a 10% YoY increase in revenue and 16% YoY growth in core EBITDA (Page 5,7).
📊 Revenue & Sales Performance
- →Biosimilars: Expect accelerated growth driven by new biosimilar launches with increasing market shares, e.g., Stelara and insulins expanding across 80+ countries. Four biosimilars each crossed USD 200 million revenue, indicating strong adoption and future growth. (Pages 6, 13, 17)
- →Generics: Growth supported by multiple upcoming product launches including liraglutide in Europe and the U.S., generic Copaxone, Everolimus (Zortress), and continued volumes from generic lenalidomide starting FY '26. (Pages 15, 10)
- →Insulin: Significant surge in global demand with capacity doubling in Malaysia; poised to become one of the largest fully integrated insulin manufacturers. Innovators withdrawing from certain markets opens opportunities. (Pages 15, 17, 13)
- →GLP-1s: Peptide portfolio, especially GLP-1s, expected to be key future growth drivers with ongoing capacity expansions. (Page 6, 15)
- →Overall: From FY '25 to '30, the company aims to launch around one new product per year, sustaining growth momentum. (Page 17)
📈 Profitability & Margins
- →FY'25 saw a consolidation and transition phase setting up for accelerated growth, with a 10% YoY increase in revenue and 16% YoY growth in core EBITDA (Page 5,7).
- →New biosimilar launches (e.g., Yesintek™) and Generics growth (Lenalidomide, Liraglutide) expected to drive stronger revenue and EBITDA growth ahead (Pages 6,15).
- →Incremental gross margin and EBITDA improvement anticipated from upcoming launches, supporting better profitability and operating leverage (Page 10).
- →R&D spend expected to moderate post ongoing development phases, stabilizing as a percentage of sales (Page 14).
- →Capex largely ramped up for capacity expansions (e.g., Malaysia insulin, peptide API), with reduced maintenance Capex forecasted beyond FY'26 (Pages 14,16).
- →GLP-1 market expansion anticipated as key future growth driver beyond FY'31 with capacity expansions planned as needed (Page 16).
- →Overall, directionally higher EBITDA growth than revenue growth is expected as new launches scale and operational efficiencies improve (Pages 10,15).
🏗️ Capital Expenditure Plans
- →Biocon plans to spend about USD 100 million in Capex over the next couple of years, primarily to enhance biologics capacities in Malaysia (Page 14).
- →A large part of this Capex focuses on increasing insulin manufacturing capacity, including a twofold expansion of drug product and drug substance capacities in Malaysia (Page 15).
- →For Generics, next year’s Capex is estimated at around USD 50 million, mostly maintenance Capex, with major ongoing programs concluding (Page 14).
- →Investment in large-scale drug substance capacity for GLP-1s was capitalized in FY'25, and a new injectable GLP-1 facility will be commissioned in FY'26; capacity expansions planned beyond 2031 based on market demand (Page 16).
- →Syngene acquired a state-of-the-art biologics facility in the U.S., expanding its global CDMO manufacturing footprint (Page 7).
💰 Fundraising & Capital Structure
- →Biocon plans to raise INR 4,500 crores through a combination of Qualified Institutional Placement (QIP) and private placement.
- →Shareholders' notice for the capital raise was sent recently, and discussions with bankers, investors, and lawyers are ongoing.
- →The first tranche of the fundraising is expected to be completed by mid-June 2025.
- →The proceeds will primarily be used to meet financial obligations, including commitments and put options arising from structured debt related to Biocon Biologics investments.
- →Not all structured debt investors have exercised their put options; the company will provide exit to those who do but will not clear the entire structured instruments from its balance sheet.
📋 Order Book & Pipeline
Key Metrics
Frequently Asked Questions
What were Biocon Ltd Q4 FY25 results?
Biosimilars: Expect accelerated growth driven by new biosimilar launches with increasing market shares, e.g., Stelara and insulins expanding across 80+ countries. FY'25 saw a consolidation and transition phase setting up for accelerated growth, with a 10% YoY increase in revenue and 16% YoY growth in core EBITDA (Page 5,7).
What is Biocon Ltd share price analysis?
Biocon Ltd currently shows a neutral. The stock trades at a P/E of 95.3 with a market cap of ₹69,295 Cr. Investors should review the full earnings analysis for detailed insights.
Is Biocon Ltd planning capital expenditure?
Biocon plans to spend about USD 100 million in Capex over the next couple of years, primarily to enhance biologics capacities in Malaysia (Page 14).
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.